Nanotechnology as a tool to advance research and treatment of non-oncologic urogenital diseases.
Nanotechnology as a tool to advance research and treatment of non-oncologic urogenital diseases.
复制标题
DOI：
10.1177/17562872221109023
复制
发表时间：
2022-01
影响因子：
2
通讯作者：
Suadicani, Sylvia O.
中科院分区：
文献类型：
--
作者：
Loloi, Justin;Babar, Mustufa;Davies, Kelvin P.;Suadicani, Sylvia O.
纳米技术代表了几乎所有科学领域的研究和创新领域，包括医学，其中基于纳米材料的产品已被开发用于诊断和治疗应用。由于其小的纳米级尺寸，这些材料表现出独特的物理和化学性质，这些性质与散装时的每个组件不同。在纳米医学中，人们越来越感兴趣的是利用这些独特的特性来设计用于递送治疗剂的纳米载体。基于纳米的药物递送平台与常规药物施用途径相比具有许多优点，因为该技术允许局部和经皮应用治疗剂，其可以绕过首过代谢，通过包封疏水性药物提高药物功效，并允许包封剂的持续和受控释放。在泌尿科，基于纳米的药物递送平台已被广泛研究并用于癌症治疗。然而，也有很大的潜力，利用纳米技术来治疗非肿瘤泌尿生殖系统疾病。我们提供了最新的研究，为纳米技术在勃起功能障碍（艾德）、膀胱过度活动症（OAB）、间质性膀胱炎/膀胱疼痛综合征（IC/BPS）和导管相关尿路感染（CTIs）领域的临床转化铺平了道路。总体而言，临床前和临床研究已证明纳米材料可用作透皮和膀胱内递送治疗剂的载体以及用于含抗菌剂的导尿管制剂以治疗非肿瘤泌尿生殖系统疾病。尽管临床转化将取决于克服监管挑战，但在普遍采用该技术治疗非肿瘤泌尿生殖系统疾病之前，这是不可避免的。
Nanotechnology represents an expanding area of research and innovation in almost every field of science, including Medicine, where nanomaterial-based products have been developed for diagnostic and therapeutic applications. Because of their small, nanoscale size, these materials exhibit unique physical and chemical properties that differ from those of each component when considered in bulk. In Nanomedicine, there is an increasing interest in harnessing these unique properties to engineer nanocarriers for the delivery of therapeutic agents. Nano-based drug delivery platforms have many advantages over conventional drug administration routes as this technology allows for local and transdermal applications of therapeutics that can bypass the first-pass metabolism, improves drug efficacy through encapsulation of hydrophobic drugs, and allows for a sustained and controlled release of encapsulated agents. In Urology, nano-based drug delivery platforms have been extensively investigated and implemented for cancer treatment. However, there is also great potential for use of nanotechnology to treat non-oncologic urogenital diseases. We provide an update on research that is paving the way for clinical translation of nanotechnology in the areas of erectile dysfunction (ED), overactive bladder (OAB), interstitial cystitis/bladder pain syndrome (IC/BPS), and catheter-associated urinary tract infections (CAUTIs). Overall, preclinical and clinical studies have proven the utility of nanomaterials both as vehicles for transdermal and intravesical delivery of therapeutic agents and for urinary catheter formulation with antimicrobial agents to treat non-oncologic urogenital diseases. Although clinical translation will be dependent on overcoming regulatory challenges, it is inevitable before there is universal adoption of this technology to treat non-oncologic urogenital diseases.
登录
查看更多内容
影响因子：
6.6
作者：
Chuang, Yao-Chi;Kuo, Hann-Chorng
通讯作者：
Kuo, Hann-Chorng
影响因子：
2.4
作者：
Aziz, M. T. Abdel;Rezq, A. M.;Yehia, H. M.
通讯作者：
Yehia, H. M.
膀胱疼痛综合征/间质性膀胱炎的神经生长因子水平升高：一项荟萃分析。
影响因子：
--
作者：
Chen W;Ye DY;Han DJ;Fu GQ;Zeng X;Lin W;Liang Y
通讯作者：
Liang Y
DOI：
10.1016/j.juro.2011.03.132
发表时间：
2011-08
期刊：
The Journal of urology
影响因子：
--
作者：
Berry SH;Elliott MN;Suttorp M;Bogart LM;Stoto MA;Eggers P;Nyberg L;Clemens JQ
通讯作者：
Clemens JQ
影响因子：
6.6
作者：
Buyse, G;Waldeck, K;Andersson, KE
通讯作者：
Andersson, KE